PCSA (Processa Pharmaceuticals) Operating Income: $-14.47 Mil (TTM As of Mar. 2026)

What is Processa Pharmaceuticals Operating Income?

Processa Pharmaceuticals PCSA +9.64% 28 Operating Income is $-14.47 Mil as of Mar. 2026. GuruFocus rates PCSA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Processa Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was $-3.33 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-14.47 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Processa Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was $-3.33 Mil. Processa Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Processa Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2026 was %.

Processa Pharmaceuticals's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Processa Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 was -563.86%. Processa Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -333,100.00%.

Processa Pharmaceuticals (NAS:PCSA) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Processa Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-13.324 * ( 1 - 0% )	/	( (2.143	+	2.583)	/ 2 )
=	-13.324	/	2.363
=	-563.86 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7.814	-	2.236	-	( 5.537	-	max(0, 2.236	-	5.671	+	5.537	))
=	2.143

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.521	-	1.98	-	( 1.691	-	max(0, 1.98	-	1.938	+	1.691	))
=	2.583

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Processa Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-13.324	/	( ( (0.004 + max(-2.102, 0))	+	(0.004 + max(-1.733, 0)) )	/	2 )
=	-13.324	/	( ( 0.004	+	0.004 )	/	2 )
=	-13.324	/	0.004
=	-333,100.00 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.134)	-	(2.236	+	0	+	0)
=	-2.102

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.247)	-	(1.98	+	0	+	0)
=	-1.733

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Processa Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as:

Operating Margin %	=	Operating Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-3.331	/	0
	=	%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Processa Pharmaceuticals Operating Income Related Terms

Processa Pharmaceuticals Operating Income Historical Data

* Premium members only.

The historical data trend for Processa Pharmaceuticals's Operating Income can be seen below:

Processa Pharmaceuticals Operating Income Chart

Processa Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Operating Income

Get a 7-Day Free Trial

-11.57

-20.26

-11.46

-12.05

-13.99

Processa Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Operating Income	Get a 7-Day Free Trial															-2.85	-3.95	-3.49	-3.70	-3.33

28GF Score

Processa Pharmaceuticals Inc PCSA

Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Processa Pharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.47 Mil.

Frequently Asked Questions Learn more about Operating Income →

What does a Operating Income of $-14.47 Mil mean?

Processa Pharmaceuticals (PCSA) has a Operating Income of $-14.47 Mil as of Mar. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Processa Pharmaceuticals and its competitors.

Is Processa Pharmaceuticals' Operating Income too high?

Processa Pharmaceuticals' current Operating Income is $-14.47 Mil. Overall, Processa Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.

How does Processa Pharmaceuticals' Operating Income compare to ELAB and MBIO?

Processa Pharmaceuticals' Operating Income of $-14.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Operating Income for a Biotechnology company?

A good Operating Income depends on the Biotechnology industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Operating Income mean?

A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Processa Pharmaceuticals and its competitors. Processa Pharmaceuticals's current Operating Income is $-14.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Processa Pharmaceuticals stock overvalued right now?

Processa Pharmaceuticals (PCSA) has a current Operating Income of $-14.47 Mil. The current Operating Income is $-14.47 Mil. Processa Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Operating Income calculated?

Operating Income is calculated from a company's financial statements. For Processa Pharmaceuticals (PCSA), the current Operating Income is $-14.47 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Processa Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies ELAB MBIO DRMA LIMN TCRT GNPX MLEC CLGN CPMV ADIL VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 601 21st Street, Suite 300, Vero Beach, FL, USA, 32960

Website https://www.processapharmaceuticals.com

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.

28GF Score

Get the complete analysis for PCSA

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.16

Price

View PCSA Analysis

See Operating Income data for all stocks →